# Surgar

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surgar

- Industry: Medical Devices & Equipment
- Headquarters: Clermont-Ferrand, France
- Website: www.surgar-surgery.com/
- Total disclosed funding: $10M
- Latest round: Series A (Sep 10, 2024)
- Investors on record: 10

## About

Based in Clermont-Ferrand, France, Surgar SAS specializes in augmented reality (AR) technology for minimally invasive surgeries, enhancing surgical precision and outcomes with innovative solutions.Surgar SAS, founded in 2019 in Clermont-Ferrand, France, focuses on augmented reality for surgical applications. CEO Nicolas Bourdel leads the company, which has raised EUR 11.000 mn in its Series A funding round on September 26, 2024, with key investors including XAnge and BNP Paribas. The company has completed 2 deals to date.Surgar SAS specializes in innovative medical technology, primarily focusing on augmented reality (AR) software designed for minimally invasive surgeries. Their core product offerings include a plug-and-play AR solution that utilizes preoperative MRI and CT scans to create detailed 3D models, displayed in real-time during surgical procedures. This technology facilitates enhanced visualization of mobile and deformable organs, improving precision in laparoscopic and robot-assisted surgeries. The company primarily serves healthcare providers across Europe and North America, aiming to transform surgical practices through advanced applications of augmented reality and artificial intelligence.Surgar SAS operates on a business-to-business model, generating revenue through software licensing agreements and service subscriptions with healthcare institutions. In 2020, the company reported a revenue of EUR 2,924.70 mn and an EBITDA of EUR -512,608.20 for the same year. Clients typically enter into long-term partnerships for access to the AR software and associated training programs, structured around annual subscription fees, allowing hospitals to provide advanced surgical solutions.Following the recent Series A funding of EUR 11.000 mn raised on September 26, 2024, Surgar SAS plans to introduce U-SURGAR, a specialized software for female patients with fibroids and adenomyosis. The funding will also support the completion and launch of L-SURGAR and K-SURGAR, targeting liver and kidney cancers. The company is poised to expand into new markets, focusing on increasing its presence in Europe and North America.

## Funding rounds

- Series A, Sep 10, 2024, $10M — Elaia Partners, XAnge, UI Investissement, Bpifrance, Supernova Invest, BNP Paribas, MH Innov, Clermont Auvergne Innovation, D-Novafund, Gsurge Consulting

## Investors

- Elaia Partners (https://capitalatlas.ai/funds/elaia-partners) — Series A
- XAnge (https://capitalatlas.ai/funds/xange) — Series A
- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Series A
- Bpifrance — Series A
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series A
- BNP Paribas — Series A
- MH Innov (https://capitalatlas.ai/funds/mh-innov) — Series A
- Clermont Auvergne Innovation — Series A
- D-Novafund — Series A
- Gsurge Consulting — Series A